与肺癌有关的重要翻译

　疾病介绍翻译在医院等医疗部门应用比较广泛，我们安徽译博翻译公司不仅擅长医疗翻译，医药翻译，疾病介绍翻译，而且配有专业医疗翻译人员，同时与多家大型医疗机构保持合作关系，以下就是我公司译员整理翻译的关于肺癌介绍的相关重要知识的翻译。
 
    Lung cancer is the most frequent and deadly malignancy worldwide and kills more people every year than colon, prostate, and breast cancer combined.Thus many efforts to improve diagnosis and therapy to increase the rate of lung cancer survival have been initiated during the last years.
 
    肺癌是世界上发病率最高且死亡威胁最大的疾病，每年因肺癌死亡的人数超过因结肠癌、前列腺癌和乳癌死亡人数的总和。为提高诊断和治疗可能性从而降低肺癌死亡率，近年来开展了大量的研究。
 
    Lung cancer is classified as non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC accounts for approximately 20% of the new cases and differs clinically and biologically from the other histological types due to its neuroendocrine differentiation. The incidence of advanced disease at the time of primary diagnosis is high in SCLC. These tumors are, however, very sensitive to chemotherapy and radiotherapy.
 
    肺癌分为非小细胞癌（NSCLC）和小细胞癌（SCLC）。新发病例中，SCLC约占20％的比例，并因其神经内分泌分化与其它组织学型存在临床和生物学差异。对于SCLC，初步诊断时进展性肺癌的发病率高。但这些肿瘤对于化疗和放疗很敏感。
 
    Neuron specific enolase (NSE) has been the marker of choice in SCLC for prognosis, monitoring the course of disease and also for supporting diagnosis.However, NSE has relatively low sensitivity in early stage disease and is also influenced by hemolysis and other factors.
 
    神经元特异烯醇化酶（NSE）已被选择用作SCLC的标记物，用于诊断和监测病程，而且还用于诊断支持。
 
    The difference in NSE levels between healthy subjects, benign disease and SCLC is also relatively small. These limitations of NSE has stimulated the search for better markers and efforts to find effective combionations of markersfor SCLC.
 
    然而，对于早期肺癌，NSE的敏感性相对较低，还受溶血和其它因素的影响。健康个体之间以及良性肺癌和SCLC之间的NSE水平差别相对较小。NSE的这些局限性激起寻找更好的SCLC标记物和有效组合标记物的研究和试验。
 
    The neuropeptide hormone Gastrin Releasing Peptide (GRP) was described more than 25 years ago as a tissue marker of SCLC, but it was not possible to measure GRP in blood due to its very short half-life. GRP is synthesised as a prohormone, ProGRP, and this precursor of GRP is stable in serum. Immunoassays for ProGRP have been developed and the determination of ProGRP (peptide 31-98) has been shown to be a useful serum marker for SCLC.
 
    25年前，神经肽激素胃泌素释放肽（GRP）被描述为SCLC的一种组织标记物，但血液中的GRP因其半衰期很短无法测量。GRP被合成为一种激素原ProGRP，GRP的这种前体在血清中是稳定的。ProGRP免疫测定已经确立，ProGRP测定（肽31-98）证实ProGRP是一种有用的SCLC血清标记物。

         我们真心希望可以以此帮助到同行业，或者医院对 肺癌相关知识的翻译与应用。